argenx (ARGX) SE “announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren’s disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren’s disease.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se: Innovative Approaches and Promising Pipeline Drive Buy Rating
- Argenx price target raised to EUR 680 from EUR 650 at Barclays
- Argenx selloff misses growth potential for PFS format, says Wedbush
- Argenx’s Promising ALKIVIA Study Results Justify Buy Rating
- Argenx SE Announces AGM Results and Key Resolutions